Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2017

02.06.2017 | Clinical Study

Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1

verfasst von: Eva Trevisson, Matteo Cassina, Enrico Opocher, Virginia Vicenzi, Marta Lucchetta, Raffaele Parrozzani, Giacomo Miglionico, Rodica Mardari, Elisabetta Viscardi, Edoardo Midena, Maurizio Clementi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Optic pathway glioma (OPG) represents the most common central nervous system tumor in children with Neurofibromatosis type-1 (NF1). Although overall survival is usually good, no clear prognostic factors have been identified so far. We assessed the natural history of OPG in a cohort of unselected patients affected by NF1. We retrospectively evaluated 414 consecutive patients affected by NF1 and referred to our NF1 clinic before age 6. Average follow-up was 11.9 years: 52 out of 414 patients had OPG with a total cumulative incidence of 15.4% at age 15 (Kaplan–Meier estimate) and a statistically significant difference according to sex. Brain and orbit MRI was performed in 44.7% of patients: 34.6% for screening purposes and 65.4% because of the presence of neurological, ocular or other symptoms. OPG was diagnosed in 12.5% of cases in the first group, whereas in 36.4% in the latter group (p = 0.001). Clinical management was conservative in most patients, while 8 of them underwent therapy mainly because of visual deterioration. OPG was diagnosed earlier in treated patients, but the difference was not statistically significant. Conversely, all patients who underwent screening MRI had normal visual outcome. In conclusion, OPG location does not correlate with need for treatment; female patients were more frequently affected by OPG but not more frequently treated. OPG diagnosis by screening MRI does not affect the natural history of the tumor.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Clementi M, Barbujani G, Turolla L, Tenconi R (1990) Neurofibromatosis-1: a maximum likelihood estimation of mutation rate. Hum Genet 84(2):116–118CrossRefPubMed Clementi M, Barbujani G, Turolla L, Tenconi R (1990) Neurofibromatosis-1: a maximum likelihood estimation of mutation rate. Hum Genet 84(2):116–118CrossRefPubMed
2.
Zurück zum Zitat Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, Brownstein BH, Collins FS (1990) Type-1 Neurofibromatosis gene—identification of a large transcript disrupted in 3 Nf1 patients. Science 249(4965):181–186. doi:10.1126/science.2134734 CrossRefPubMed Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, Brownstein BH, Collins FS (1990) Type-1 Neurofibromatosis gene—identification of a large transcript disrupted in 3 Nf1 patients. Science 249(4965):181–186. doi:10.​1126/​science.​2134734 CrossRefPubMed
5.
Zurück zum Zitat Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A (2007) Guidelines for the diagnosis and management of individuals with Neurofibromatosis 1. J Med Genet 44(2):81–88. doi:10.1136/jmg.2006.045906 CrossRefPubMed Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A (2007) Guidelines for the diagnosis and management of individuals with Neurofibromatosis 1. J Med Genet 44(2):81–88. doi:10.​1136/​jmg.​2006.​045906 CrossRefPubMed
6.
Zurück zum Zitat Listernick R, Louis DN, Packer RJ, Gutmann DH (1997) Optic pathway gliomas in children with Neurofibromatosis 0.1. Consensus statement from the NF1 optic pathway glioma task force. Ann Neurol 41(2):143–149. doi:10.1002/ana.410410204 CrossRefPubMed Listernick R, Louis DN, Packer RJ, Gutmann DH (1997) Optic pathway gliomas in children with Neurofibromatosis 0.1. Consensus statement from the NF1 optic pathway glioma task force. Ann Neurol 41(2):143–149. doi:10.​1002/​ana.​410410204 CrossRefPubMed
8.
Zurück zum Zitat Listernick R, Ferner RE, Piersall L, Sharif S, Gutmann DH, Charrow J (2004) Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 63(10):1944–1946CrossRefPubMed Listernick R, Ferner RE, Piersall L, Sharif S, Gutmann DH, Charrow J (2004) Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 63(10):1944–1946CrossRefPubMed
10.
11.
Zurück zum Zitat Balcer LJ, Liu GT, Heller G, Bilaniuk L, Volpe NJ, Galetta SL, Molloy PT, Phillips PC, Janss AJ, Vaughn S, Maguire MG (2001) Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 131(4):442–445CrossRefPubMed Balcer LJ, Liu GT, Heller G, Bilaniuk L, Volpe NJ, Galetta SL, Molloy PT, Phillips PC, Janss AJ, Vaughn S, Maguire MG (2001) Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 131(4):442–445CrossRefPubMed
12.
Zurück zum Zitat Taylor T, Jaspan T, Milano G, Gregson R, Parker T, Ritzmann T, Benson C, Walker D, Group PS (2008) Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 81(970):761–766. doi:10.1259/bjr/65246351 CrossRefPubMed Taylor T, Jaspan T, Milano G, Gregson R, Parker T, Ritzmann T, Benson C, Walker D, Group PS (2008) Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 81(970):761–766. doi:10.​1259/​bjr/​65246351 CrossRefPubMed
13.
Zurück zum Zitat Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14(6):790–797. doi:10.1093/neuonc/nos076 CrossRefPubMedPubMedCentral Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14(6):790–797. doi:10.​1093/​neuonc/​nos076 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Tow SL, Chandela S, Miller NR, Avellino AM (2003) Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol 28(4):262–270CrossRefPubMed Tow SL, Chandela S, Miller NR, Avellino AM (2003) Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol 28(4):262–270CrossRefPubMed
15.
Zurück zum Zitat Prada CE, Hufnagel RB, Hummel TR, Lovell AM, Hopkin RJ, Saal HM, Schorry EK (2015) The use of magnetic resonance imaging screening for optic pathway gliomas in children with Neurofibromatosis type 1. J Pediatr 167(4):851–856 e851. doi:10.1016/j.jpeds.2015.07.001 CrossRefPubMed Prada CE, Hufnagel RB, Hummel TR, Lovell AM, Hopkin RJ, Saal HM, Schorry EK (2015) The use of magnetic resonance imaging screening for optic pathway gliomas in children with Neurofibromatosis type 1. J Pediatr 167(4):851–856 e851. doi:10.​1016/​j.​jpeds.​2015.​07.​001 CrossRefPubMed
16.
18.
Zurück zum Zitat Blanchard G, Lafforgue MP, Lion-Francois L, Kemlin I, Rodriguez D, Castelnau P, Carneiro M, Meyer P, Rivier F, Barbarot S, Chaix Y, network NFF (2016) Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol 20(2):275–281. doi:10.1016/j.ejpn.2015.12.002 CrossRefPubMed Blanchard G, Lafforgue MP, Lion-Francois L, Kemlin I, Rodriguez D, Castelnau P, Carneiro M, Meyer P, Rivier F, Barbarot S, Chaix Y, network NFF (2016) Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol 20(2):275–281. doi:10.​1016/​j.​ejpn.​2015.​12.​002 CrossRefPubMed
19.
Zurück zum Zitat King A, Listernick R, Charrow J, Piersall L, Gutmann DH (2003) Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 122A(2):95–99. doi:10.1002/ajmg.a.20211 CrossRefPubMed King A, Listernick R, Charrow J, Piersall L, Gutmann DH (2003) Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 122A(2):95–99. doi:10.​1002/​ajmg.​a.​20211 CrossRefPubMed
20.
Zurück zum Zitat Dalla Via P, Opocher E, Pinello ML, Calderone M, Viscardi E, Clementi M, Battistella PA, Laverda AM, Da Dalt L, Perilongo G (2007) Visual outcome of a cohort of children with Neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol 9(4):430–437. doi:10.1215/15228517-2007-031 CrossRefPubMed Dalla Via P, Opocher E, Pinello ML, Calderone M, Viscardi E, Clementi M, Battistella PA, Laverda AM, Da Dalt L, Perilongo G (2007) Visual outcome of a cohort of children with Neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol 9(4):430–437. doi:10.​1215/​15228517-2007-031 CrossRefPubMed
21.
Zurück zum Zitat Kalin-Hajdu E, Decarie JC, Marzouki M, Carret AS, Ospina LH (2014) Visual acuity of children treated with chemotherapy for optic pathway gliomas. Pediatr Blood Cancer 61(2):223–227. doi:10.1002/pbc.24726 CrossRefPubMed Kalin-Hajdu E, Decarie JC, Marzouki M, Carret AS, Ospina LH (2014) Visual acuity of children treated with chemotherapy for optic pathway gliomas. Pediatr Blood Cancer 61(2):223–227. doi:10.​1002/​pbc.​24726 CrossRefPubMed
22.
Zurück zum Zitat Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference (1988) Arch Neurol 45(5):575–578 Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference (1988) Arch Neurol 45(5):575–578
24.
Zurück zum Zitat Parrozzani R, Clementi M, Kotsafti O, Miglionico G, Trevisson E, Orlando G, Pilotto E, Midena E (2013) Optical coherence tomography in the diagnosis of optic pathway gliomas. Invest Ophthalmol Vis Sci 54(13):8112–8118. doi:10.1167/iovs.13-13093 CrossRefPubMed Parrozzani R, Clementi M, Kotsafti O, Miglionico G, Trevisson E, Orlando G, Pilotto E, Midena E (2013) Optical coherence tomography in the diagnosis of optic pathway gliomas. Invest Ophthalmol Vis Sci 54(13):8112–8118. doi:10.​1167/​iovs.​13-13093 CrossRefPubMed
25.
Zurück zum Zitat Pan Y, Tarczy-Hornoch K, Cotter SA, Wen G, Borchert MS, Azen SP, Varma R, Grp M (2009) Visual acuity norms in pre-school children: the multi-ethnic pediatric eye disease study. Optom Vis Sci 86 (6):607–612CrossRefPubMedPubMedCentral Pan Y, Tarczy-Hornoch K, Cotter SA, Wen G, Borchert MS, Azen SP, Varma R, Grp M (2009) Visual acuity norms in pre-school children: the multi-ethnic pediatric eye disease study. Optom Vis Sci 86 (6):607–612CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat International Classification of Impairments, Disabilities, and Handicaps. A manual of classification relating to the consequences of disease (1980). World Health Organization 1980 edn International Classification of Impairments, Disabilities, and Handicaps. A manual of classification relating to the consequences of disease (1980). World Health Organization 1980 edn
27.
Zurück zum Zitat Friedrich RE, Nuding MA (2016) Optic pathway glioma and cerebral focal abnormal signal intensity in patients with Neurofibromatosis type 1: characteristics, treatment choices and follow-up in 134 affected individuals and a brief review of the literature. Anticancer Res 36(8):4095–4121PubMed Friedrich RE, Nuding MA (2016) Optic pathway glioma and cerebral focal abnormal signal intensity in patients with Neurofibromatosis type 1: characteristics, treatment choices and follow-up in 134 affected individuals and a brief review of the literature. Anticancer Res 36(8):4095–4121PubMed
28.
Zurück zum Zitat Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, Evans DG (2006) Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24(16):2570–2575. doi:10.1200/JCO.2005.03.8349 CrossRefPubMed Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, Evans DG (2006) Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24(16):2570–2575. doi:10.​1200/​JCO.​2005.​03.​8349 CrossRefPubMed
29.
Zurück zum Zitat Dodge HW Jr, Love JG, Craig WM, Dockerty MB, Kearns TP, Holman CB, Hayles AB (1958) Gliomas of the optic nerves. AMA. Arch Neurol Psychiatry 79(6):607–621CrossRef Dodge HW Jr, Love JG, Craig WM, Dockerty MB, Kearns TP, Holman CB, Hayles AB (1958) Gliomas of the optic nerves. AMA. Arch Neurol Psychiatry 79(6):607–621CrossRef
31.
Zurück zum Zitat Johnson KJ, Scheurer ME, Woehrer A, Wiemels J (2016) Evolving evidence on tumor and germline genetic classification of gliomas: implications for etiology and survival studies. Clin Neuropathol 35(1):31–38. doi:10.5414/NP300917 CrossRefPubMed Johnson KJ, Scheurer ME, Woehrer A, Wiemels J (2016) Evolving evidence on tumor and germline genetic classification of gliomas: implications for etiology and survival studies. Clin Neuropathol 35(1):31–38. doi:10.​5414/​NP300917 CrossRefPubMed
33.
Zurück zum Zitat Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE (2004) Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet A 127 A(3):224–229. doi:10.1002/ajmg.a.20650 CrossRef Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE (2004) Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet A 127 A(3):224–229. doi:10.​1002/​ajmg.​a.​20650 CrossRef
34.
Zurück zum Zitat Massry GG, Morgan CF, Chung SM (1997) Evidence of optic pathway gliomas after previously negative neuroimaging. Ophthalmology 104(6):930–935CrossRefPubMed Massry GG, Morgan CF, Chung SM (1997) Evidence of optic pathway gliomas after previously negative neuroimaging. Ophthalmology 104(6):930–935CrossRefPubMed
35.
Zurück zum Zitat Listernick R, Charrow J, Greenwald M (1992) Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results. J Pediatr 121(4):584–587CrossRefPubMed Listernick R, Charrow J, Greenwald M (1992) Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results. J Pediatr 121(4):584–587CrossRefPubMed
36.
Zurück zum Zitat Doganis D, Pourtsidis A, Tsakiris K, Baka M, Kouri A, Bouhoutsou D, Varvoutsi M, Servitzoglou M, Dana H, Kosmidis H (2016) Optic pathway glioma in children: 10 years of experience in a single institution. Pediatr Hematol Oncol 33(2):102–108. doi:10.3109/08880018.2016.1155101 CrossRefPubMed Doganis D, Pourtsidis A, Tsakiris K, Baka M, Kouri A, Bouhoutsou D, Varvoutsi M, Servitzoglou M, Dana H, Kosmidis H (2016) Optic pathway glioma in children: 10 years of experience in a single institution. Pediatr Hematol Oncol 33(2):102–108. doi:10.​3109/​08880018.​2016.​1155101 CrossRefPubMed
37.
Zurück zum Zitat Gottschalk S, Tavakolian R, Buske A, Tinschert S, Lehmann R (1999) Spontaneous remission of chiasmatic/hypothalamic masses in Neurofibromatosis type 1: report of two cases. Neuroradiology 41(3):199–201CrossRefPubMed Gottschalk S, Tavakolian R, Buske A, Tinschert S, Lehmann R (1999) Spontaneous remission of chiasmatic/hypothalamic masses in Neurofibromatosis type 1: report of two cases. Neuroradiology 41(3):199–201CrossRefPubMed
38.
Zurück zum Zitat Parsa CF, Hoyt CS, Lesser RL, Weinstein JM, Strother CM, Muci-Mendoza R, Ramella M, Manor RS, Fletcher WA, Repka MX, Garrity JA, Ebner RN, Monteiro MLR, McFadzean RM, Rubtsova IV, Hoyt WF (2001) Spontaneous regression of optic gliomas—thirteen cases documented by serial neuroimaging. Arch Ophthalmol-Chic 119(4):516–529CrossRef Parsa CF, Hoyt CS, Lesser RL, Weinstein JM, Strother CM, Muci-Mendoza R, Ramella M, Manor RS, Fletcher WA, Repka MX, Garrity JA, Ebner RN, Monteiro MLR, McFadzean RM, Rubtsova IV, Hoyt WF (2001) Spontaneous regression of optic gliomas—thirteen cases documented by serial neuroimaging. Arch Ophthalmol-Chic 119(4):516–529CrossRef
Metadaten
Titel
Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1
verfasst von
Eva Trevisson
Matteo Cassina
Enrico Opocher
Virginia Vicenzi
Marta Lucchetta
Raffaele Parrozzani
Giacomo Miglionico
Rodica Mardari
Elisabetta Viscardi
Edoardo Midena
Maurizio Clementi
Publikationsdatum
02.06.2017
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2517-6

Weitere Artikel der Ausgabe 2/2017

Journal of Neuro-Oncology 2/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.